Meu SciELO
Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Nutrición Hospitalaria
versão On-line ISSN 1699-5198versão impressa ISSN 0212-1611
Resumo
PAZ, R. De e HERNANDEZ-NAVARRO, F.. Management, prevention and control of pernicious anemia. Nutr. Hosp. [online]. 2005, vol.20, n.6, pp.433-435. ISSN 1699-5198.
Pernicious anemia is the most frequent cause of megaloblastic anemia in our area, and it is the result of a vitamin B12 deficiency due, itself, to the de-crease or absence of intrinsic factor (IF) because of gastric mucosa atrophy or autoimmune destruction of IF-producing parietal cells. With the existence of a severe gastric atrophy, there is a decrease in acid and IF production and a further change in vitamin B12 absorption. Fifty percent of the cases are associated to anti-IF antibodies, which presence in other autoimmune diseases is exceptional. In patients with pernicious anemia, measurement of anti-IF antibodies has high specificity (95%); however, measurement of anti-parietal cells antibodies has low specificity. The first-choice treatment is adminis-tration of vitamin B12 intramuscularly. The regimen is the administration of 1 mg of vitamin B12 daily for one week, weekly thereafter for one month and, then, every 2-3 months for life.
Palavras-chave : Vitamin B 12; Intrinsic factor; Megaloblastic anemia.